Research Analysts Set Expectations for Immunic Q1 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at HC Wainwright decreased their Q1 2026 earnings per share estimates for shares of Immunic in a report released on Monday, March 2nd. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.20) per share for the quarter, down from their previous forecast of ($0.15). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Immunic’s Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.63) EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at ($0.30) EPS, FY2029 earnings at ($0.20) EPS and FY2030 earnings at ($0.08) EPS.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02).

A number of other analysts have also commented on IMUX. Roth Mkm started coverage on Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 target price for the company. Chardan Capital upgraded Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. Brookline Capital Acquisition raised Immunic to a “strong-buy” rating in a research report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Finally, D. Boral Capital decreased their price objective on shares of Immunic from $8.00 to $4.00 and set a “buy” rating for the company in a report on Friday, February 13th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $6.00.

Immunic Stock Up 9.3%

Shares of IMUX opened at $1.17 on Wednesday. Immunic has a twelve month low of $0.51 and a twelve month high of $1.35. The company has a market capitalization of $152.64 million, a P/E ratio of -1.67 and a beta of 1.46. The firm has a 50 day moving average of $0.73 and a 200 day moving average of $0.77.

Institutional Investors Weigh In On Immunic

A number of hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC purchased a new position in shares of Immunic during the 4th quarter valued at about $2,337,000. Millennium Management LLC raised its stake in Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock worth $1,825,000 after acquiring an additional 2,888,829 shares during the period. Laurion Capital Management LP boosted its position in shares of Immunic by 106.3% in the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after purchasing an additional 2,000,000 shares during the period. Marshall Wace LLP increased its stake in shares of Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock worth $541,000 after purchasing an additional 486,468 shares in the last quarter. Finally, Connective Capital Management LLC purchased a new stake in shares of Immunic in the fourth quarter worth $161,000. Institutional investors own 51.82% of the company’s stock.

Key Immunic News

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright raised several near‑term estimates — including Q3 2026 and Q4 2026 EPS and lifted FY2026 and FY2027 forecasts modestly (e.g., FY2026 from ($0.67) to ($0.63), FY2027 from ($0.53) to ($0.50)). These upward revisions and the continued “Buy” rating provide constructive analyst support for IMUX.
• Neutral Sentiment: Management will present at investor conferences in March (Leerink Partners Global Healthcare Conference and additional investor meetings). These events give investors fresh management access and potential clinical or program updates that could move the stock. Immunic to Participate in Investor Conferences in March
• Negative Sentiment: HC Wainwright lowered some near‑term quarter estimates — cutting Q1 2026 (to ($0.20) from ($0.15)) and trimming Q2 2026 (to ($0.17) from ($0.16)). Those downgrades signal continued cash‑burn/late‑stage biotech execution risk.
• Negative Sentiment: The firm also reduced multi‑year outlooks for FY2028 and FY2029 (e.g., FY2029 moved to ($0.20) from ($0.10)), indicating a dimmer mid‑term profit trajectory than previously modeled.
• Negative Sentiment: HC Wainwright lowered its price target to $5.00 (while retaining Buy), a downgrade in valuation terms that could cap upside until clearer clinical or commercial milestones are delivered. HC Wainwright Lowers Immunic (NASDAQ:IMUX) Price Target to $5.00

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.